• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Waters Corporation (NYSE: WAT) Reports Third Quarter 2024 Financial Results

    11/1/24 6:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $WAT alert in real time by email

    Highlights

    • Sales of $740 million exceeded guidance, grew 4% as reported and 4% in constant currency
    • Instruments returned to growth; recurring revenue grew high single-digits in constant currency
    • All reported regions returned to growth in the quarter; sales grew across all end markets, led by Pharma & Industrial
    • GAAP EPS of $2.71 and non-GAAP EPS of $2.93 significantly exceeded guidance, led by strong operational performance and better-than-expected market conditions
    • Raised full-year sales and EPS guidance, with 5% to 7% constant currency growth expected in the fourth quarter

    Third Quarter 2024

    MILFORD, Mass., Nov. 1, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced its financial results for the third quarter of 2024.

    Sales for the third quarter of 2024 were $740 million, an increase of 4% as reported, compared to sales of $712 million for the third quarter of 2023. Currency translation had minimal impact on sales.

    On a GAAP basis, diluted earnings per share (EPS) for the third quarter of 2024 was $2.71, compared to $2.27 for the third quarter of 2023. On a non-GAAP basis, EPS was $2.93, compared to $2.84 for the third quarter of 2023. This includes a headwind of approximately 2% due to unfavorable foreign exchange.

    "We delivered exceptional third quarter results, fueled by new product adoption and improved customer spending trends," said Dr. Udit Batra, President & CEO, Waters Corporation. "Instruments returned to growth sooner than expected, as liquid chromatography sales to pharma and industrial customers turned positive."

    Dr. Batra continued, "Looking ahead, our strong commercial execution, competitive product portfolio, and excellent operational performance give us confidence in the long-term outlook for Waters."

    Other Highlights

    During the third quarter of 2024, sales into the pharmaceutical market increased 2% as reported and 3% in constant currency. Sales into the industrial market increased 9% as reported and 7% in constant currency. Sales into the academic and government market increased 2% as reported and were flat in constant currency.

    During the quarter, instrument system sales increased 1% as reported and in constant currency. Recurring revenues, which represent the combination of service and precision chemistries, increased 6% as reported and 7% in constant currency.

    Geographically, sales in Asia during the quarter increased 5% as reported and 6% in constant currency. Sales in the Americas increased 1% as reported and in constant currency. Sales in Europe increased 6% as reported and 4% in constant currency.

    Unless otherwise noted, sales growth and decline percentages are presented on an as-reported basis. A description and reconciliation of GAAP to non-GAAP results appear in the tables below and can be found on the Company's website www.waters.com in the Investor Relations section.

    Full-Year and Fourth Quarter 2024 Financial Guidance

    Full-Year 2024 Financial Guidance

    The Company is raising its full-year 2024 sales guidance, and now expects organic constant currency sales growth to be in the range of -0.9% to -0.3%. Currency translation is expected to decrease full-year sales growth by 1.2%. M&A contribution from the Wyatt transaction covering the first four-and-a-half months of the year has added 1.3% to full-year reported sales. The resulting full-year 2024 reported sales growth is expected in the range of -0.8% to -0.2%.

    The Company is also raising its full-year 2024 non-GAAP EPS guidance to now be in the range of $11.67 to $11.87, which includes an estimated headwind of approximately 3% due to unfavorable foreign exchange.

    Please refer to the tables below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the full year.

    Fourth Quarter 2024 Financial Guidance

    The Company expects fourth quarter 2024 constant currency sales growth to be in the range of +5.0% to +7.0%. Currency translation is expected to decrease fourth quarter sales growth by 1.7%. The resulting fourth quarter 2024 reported sales growth is expected in the range of +3.3% to +5.3%.

    The Company expects fourth quarter 2024 non-GAAP EPS to be in the range of $3.90 to $4.10, which includes an estimated headwind of approximately 3% due to unfavorable foreign exchange.

    Please refer to the tables below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the fourth quarter.

    Conference Call Details

    Waters Corporation will webcast its third quarter 2024 financial results conference call today, November 1, 2024, at 8:00 a.m. Eastern Time. To listen to the call and see the accompanying slide presentation, please visit www.waters.com, select "Investor Relations" under the "About Waters" section, navigate to "Events & Presentations," and click on the "Webcast." A replay will be available through November 29, 2024, on the same website by webcast and also by phone at (888) 282-0031.

    About Waters Corporation

    Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. With approximately 7,500 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries. For more information, visit www.waters.com.

    Non-GAAP Financial Measures

    This press release contains financial measures, such as organic constant currency growth rates, adjusted operating income, adjusted net income, adjusted earnings per diluted share and free cash flow, among others, which are considered "non-GAAP" financial measures under applicable U.S. Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP). The Company's definitions of these non-GAAP measures may differ from similarly titled measures used by others. The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of the Company's historical operating results, comparison to competitors' operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company's business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this release.

    Cautionary Statement

    This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "feels", "believes", "anticipates", "plans", "expects", "intends", "suggests", "appears", "estimates", "projects" and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements. The Company's actual future results may differ significantly from the results discussed in the forward- looking statements within this release for a variety of reasons, including and without limitation, risks related to, and expectations or ability to realize commercial success of the Wyatt transaction; the impact of this transaction on the Company's business, anticipated progress on Waters' research programs, development of new analytical instruments and associated software or consumables, manufacturing development and capabilities; the increased indebtedness of the Company as a result of the Wyatt transaction, the repayment of which could impact the Company's future results, market prospects for its products and sales and earnings guidance; foreign currency exchange rate fluctuations potentially affecting translation of the Company's future non-U.S. operating results, particularly when a foreign currency weakens against the U.S. dollar; current global economic, sovereign and political conditions and uncertainties, including the effect of new or proposed tariff or trade regulations as well as other new or changed domestic and foreign laws, regulations and policies; changes in inflation and interest rates; the impacts and costs of war, in particular as a result of the ongoing conflicts between Russia and Ukraine and in the Middle East, and the possibility of further escalation resulting in new geopolitical and regulatory instability; the Chinese government's ongoing tightening of restrictions on procurement by government-funded customers; the Company's ability to access capital, maintain liquidity and service the Company's debt in volatile market conditions; risks related to the effects of any pandemic on our business, financial condition, results of operations and prospects; changes in timing and demand for the Company's products among the Company's customers and various market sectors, particularly as a result of fluctuations in their expenditures or ability to obtain funding; the ability to realize the expected benefits related to the Company's various cost-saving initiatives, including workforce reductions and organizational restructurings; the introduction of competing products by other companies and loss of market share, as well as pressures on prices from competitors and/or customers; changes in the competitive landscape as a result of changes in ownership, mergers and continued consolidation among the Company's competitors; regulatory, economic and competitive obstacles to new product introductions; lack of acceptance of new products and inability to grow organically through innovation; rapidly changing technology and product obsolescence; risks associated with previous or future acquisitions, strategic investments, joint ventures and divestitures, including risks associated with achieving the anticipated financial results and operational synergies; contingent purchase price payments and expansion of our business into new or developing markets; risks associated with unexpected disruptions in operations; failure to adequately protect the Company's intellectual property, infringement of intellectual property rights of third parties and inability to obtain licenses on commercially reasonable terms; the Company's ability to acquire adequate sources of supply and its reliance on outside contractors for certain components and modules, as well as disruptions to its supply chain; risks associated with third-party sales intermediaries and resellers; the impact and costs of changes in statutory or contractual tax rates in jurisdictions in which the Company operates as well as shifts in taxable income among jurisdictions with different effective tax rates, the outcome of ongoing and future tax examinations and changes in legislation affecting the Company's effective tax rate; the Company's ability to attract and retain qualified employees and management personnel; risks associated with cybersecurity and technology, including attempts by third parties to defeat the security measures of the Company and its third-party partners; increased regulatory burdens as the Company's business evolves, especially with respect to the U.S. Food and Drug Administration and U.S. Environmental Protection Agency, among others, and in connection with government contracts; regulatory, environmental and logistical obstacles affecting the distribution of the Company's products, completion of purchase order documentation and the ability of customers to obtain letters of credit or other financing alternatives; risks associated with litigation and other legal and regulatory proceedings; and the impact and costs incurred from changes in accounting principles and practices. Such factors and others are discussed more fully in the sections entitled "Forward-Looking Statements" and "Risk Factors" of the Company's annual report on Form 10-K for the year ended December 31, 2023, as well as in the sections entitled "Special Note Regarding Forward-Looking Statements" and "Risk Factors" of the Company's quarterly reports on Form 10-Q for the quarterly periods ended March 30, 2024 and June 29, 2024, as filed with the Securities and Exchange Commission ("SEC"), which discussions are incorporated by reference in this release, as updated by the Company's future filings with the SEC. The forward-looking statements included in this release represent the Company's estimates or views as of the date of this release and should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this release. Except as required by law, the Company does not assume any obligation to update any forward-looking statements.

    Waters Corporation and Subsidiaries

    Consolidated Statements of Operations

    (In thousands, except per share data)

    (Unaudited)































    Three Months Ended



    Nine Months Ended



    September 28,

    2024



    September 30,

    2023



    September 28,

    2024



    September 30,

    2023

















    Net sales

    $               740,305



    $               711,692



    $            2,085,673



    $            2,136,942

















    Costs and operating expenses:















    Cost of sales

    301,655



    291,407



    851,685



    876,863

    Selling and administrative expenses 

    169,097



    186,748



    516,880



    555,657

    Research and development expenses 

    45,336



    41,995



    136,113



    130,559

    Purchased intangibles amortization 

    11,759



    12,116



    35,337



    20,410

    Litigation provision

    1,326



    -



    11,568



    -

















    Operating income 

    211,132



    179,426



    534,090



    553,453

















    Other (expense) income, net

    (338)



    328



    1,619



    1,364

    Interest expense, net

    (17,177)



    (26,559)



    (57,824)



    (56,174)

















    Income from operations before income taxes

    193,617



    153,195



    477,885



    498,643

















    Provision for income taxes

    32,114



    18,643



    71,449



    72,614

















    Net income

    $               161,503



    $               134,552



    $               406,436



    $               426,029

































    Net income per basic common share

    $                     2.72



    $                     2.28



    $                     6.85



    $                     7.21

















    Weighted-average number of basic common shares

    59,367



    59,093



    59,314



    59,061

































    Net income per diluted common share

    $                     2.71



    $                     2.27



    $                     6.83



    $                     7.19

















    Weighted-average number of diluted common shares and equivalents

    59,504



    59,255



    59,471



    59,262

     

    Waters Corporation and Subsidiaries

    Reconciliation of GAAP to Adjusted Non-GAAP

    Net Sales by Operating Segments, Products & Services, Geography and Markets

    Three Months Ended September 28, 2024 and September 30, 2023

    (In thousands)

































































    Constant











    Three Months Ended



    Percent



    Impact of



    Currency











    September 28, 2024



    September 30, 2023



    Change



    Currency



    Growth Rate (a)

































    NET SALES - OPERATING SEGMENTS

























































    Waters





    $

    655,652



    $

    629,348



    4 %



    0 %



    4 %

    TA









    84,653





    82,344



    3 %



    1 %



    2 %

































    Total







    $

    740,305



    $

    711,692



    4 %



    0 %



    4 %

































































    NET SALES - PRODUCTS & SERVICES

























































    Instruments





    $

    323,076



    $

    319,431



    1 %



    0 %



    1 %

































    Service







    278,294





    263,611



    6 %



    0 %



    6 %

    Chemistry







    138,935





    128,650



    8 %



    0 %



    8 %

    Total Recurring







    417,229





    392,261



    6 %



    (1 %)



    7 %

































    Total







    $

    740,305



    $

    711,692



    4 %



    0 %



    4 %

































































    NET SALES - GEOGRAPHY

























































    Asia







    $

    251,329



    $

    238,228



    5 %



    (1 %)



    6 %

    Americas







    279,136





    275,479



    1 %



    0 %



    1 %

    Europe







    209,840





    197,985



    6 %



    2 %



    4 %

































    Total







    $

    740,305



    $

    711,692



    4 %



    0 %



    4 %

































































    NET SALES - MARKETS

























































    Pharmaceutical





    $

    430,138



    $

    421,535



    2 %



    (1 %)



    3 %

    Industrial







    227,740





    209,449



    9 %



    2 %



    7 %

    Academic & Government





    82,427





    80,708



    2 %



    2 %



    0 %

































    Total







    $

    740,305



    $

    711,692



    4 %



    0 %



    4 %

































































    (a)

    The Company believes that referring to comparable constant currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation's net sales. Constant currency growth, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period. See description of non-GAAP financial measures contained in this release.

     



    Waters Corporation and Subsidiaries



    Reconciliation of GAAP to Adjusted Non-GAAP



    Net Sales by Operating Segments, Products & Services, Geography and Markets



    Nine Months Ended September 28, 2024 and September 30, 2023



    (In thousands)









































    Organic 





































    Constant













    Nine Months Ended



    Percent



    Impact of



    Impact of



    Currency













    September 28, 2024



    September 30, 2023



    Change



    Currency



    Acquisitions



    Growth Rate (a)









































    NET SALES - OPERATING SEGMENTS





































































    Waters





    $

    1,840,112



    $

    1,884,658



    (2 %)



    (1 %)



    2 %



    (3 %)



    TA









    245,561





    252,284



    (3 %)



    (1 %)



    0 %



    (2 %)









































    Total







    $

    2,085,673



    $

    2,136,942



    (2 %)



    (1 %)



    2 %



    (3 %)















































































    NET SALES - PRODUCTS & SERVICES





































































    Instruments





    $

    859,079



    $

    964,380



    (11 %)



    0 %



    3 %



    (14 %)









































    Service







    812,367





    774,478



    5 %



    (1 %)



    1 %



    5 %



    Chemistry







    414,227





    398,084



    4 %



    (1 %)



    0 %



    5 %



    Total Recurring







    1,226,594





    1,172,562



    5 %



    (1 %)



    1 %



    5 %









































    Total







    $

    2,085,673



    $

    2,136,942



    (2 %)



    (1 %)



    2 %



    (3 %)















































































    NET SALES - GEOGRAPHY





































































    Asia







    $

    696,319



    $

    745,932



    (7 %)



    (3 %)



    1 %



    (5 %)



    Americas







    794,775





    804,827



    (1 %)



    0 %



    3 %



    (4 %)



    Europe







    594,579





    586,183



    1 %



    2 %



    2 %



    (3 %)









































    Total







    $

    2,085,673



    $

    2,136,942



    (2 %)



    (1 %)



    2 %



    (3 %)















































































    NET SALES - MARKETS





































































    Pharmaceutical





    $

    1,220,092



    $

    1,233,177



    (1 %)



    (1 %)



    2 %



    (2 %)



    Industrial







    644,459





    648,754



    (1 %)



    0 %



    1 %



    (2 %)



    Academic & Government





    221,122





    255,011



    (13 %)



    1 %



    2 %



    (16 %)









































    Total







    $

    2,085,673



    $

    2,136,942



    (2 %)



    (1 %)



    2 %



    (3 %)















































































    (a)

    The Company believes that referring to comparable organic constant currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation's net sales. Organic constant currency growth, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period and excluding the impact of acquisitions made within twelve months of the acquisition close date. See description of non-GAAP financial measures contained in this release.

     

    Waters Corporation and Subsidiaries

    Reconciliation of GAAP to Adjusted Non-GAAP Financials

    Three and Nine Months Ended September 28, 2024 and September 30, 2023

    (In thousands, except per share data)





































































































    Income from



























































    Operations





























    Selling &





    Research &











    Operating





    Other





    before





    Provision for











    Diluted











    Administrative





    Development





    Operating





    Income





    (Expense)





    Income





    Income





    Net





    Earnings











    Expenses(a)





    Expenses





    Income





    Percentage





    Income





    Taxes





    Taxes





    Income





    per Share

    Three Months Ended September 28, 2024























































    GAAP





    $

    182,182



    $

    45,336



    $

    211,132





    28.5 %



    $

    (338)



    $

    193,617



    $

    32,114



    $

    161,503



    $

    2.71

    Adjustments:



























































    Purchased intangibles amortization (b)





    (11,759)





    -





    11,759





    1.6 %





    -





    11,759





    2,814





    8,945





    0.15



    Litigation provision (c)





    (1,326)





    -





    1,326





    0.2 %





    -





    1,326





    318





    1,008





    0.02



    Restructuring costs and certain other items (d)





    (1,194)





    -





    1,194





    0.2 %





    -





    1,194





    282





    912





    0.02



    Retention bonus obligation (f)





    (1,909)





    (636)





    2,545





    0.3 %





    -





    2,545





    611





    1,934





    0.03

    Adjusted Non-GAAP



    $

    165,994



    $

    44,700



    $

    227,956





    30.8 %



    $

    (338)



    $

    210,441



    $

    36,139



    $

    174,302



    $

    2.93





























































    Three Months Ended September 30, 2023























































    GAAP





    $

    198,864



    $

    41,995



    $

    179,426





    25.2 %



    $

    328



    $

    153,195



    $

    18,643



    $

    134,552



    $

    2.27

    Adjustments:



























































    Purchased intangibles amortization (b)





    (12,116)





    -





    12,116





    1.7 %





    -





    12,116





    2,901





    9,215





    0.16



    Restructuring costs and certain other items (d)





    (24,057)





    -





    24,057





    3.4 %





    (651)





    23,406





    5,387





    18,019





    0.30



    Acquisition related costs (e)





    (1,263)





    -





    1,263





    0.2 %





    -





    1,263





    303





    960





    0.02



    Retention bonus obligation (f)





    (5,725)





    (1,909)





    7,634





    1.1 %





    -





    7,634





    1,832





    5,802





    0.10

    Adjusted Non-GAAP



    $

    155,703



    $

    40,086



    $

    224,496





    31.5 %



    $

    (323)



    $

    197,614



    $

    29,066



    $

    168,548



    $

    2.84





























































    Nine Months Ended September 28, 2024























































    GAAP





    $

    563,785



    $

    136,113



    $

    534,090





    25.6 %



    $

    1,619



    $

    477,885



    $

    71,449



    $

    406,436



    $

    6.83

    Adjustments:



























































    Purchased intangibles amortization (b)





    (35,337)





    -





    35,337





    1.7 %





    -





    35,337





    8,456





    26,881





    0.45



    Litigation provision and settlement (c)





    (11,568)





    -





    11,568





    0.6 %





    -





    11,568





    2,776





    8,792





    0.15



    Restructuring costs and certain other items (d)





    (10,680)





    -





    10,680





    0.5 %





    -





    10,680





    2,617





    8,063





    0.14



    Retention bonus obligation (f)





    (11,451)





    (3,817)





    15,268





    0.7 %





    -





    15,268





    3,664





    11,604





    0.20

    Adjusted Non-GAAP



    $

    494,749



    $

    132,296



    $

    606,943





    29.1 %



    $

    1,619



    $

    550,738



    $

    88,962



    $

    461,776



    $

    7.76





























































    Nine Months Ended September 30, 2023























































    GAAP





    $

    576,067



    $

    130,559



    $

    553,453





    25.9 %



    $

    1,364



    $

    498,643



    $

    72,614



    $

    426,029



    $

    7.19

    Adjustments:



























































    Purchased intangibles amortization (b)





    (20,410)





    -





    20,410





    1.0 %





    -





    20,410





    4,852





    15,558





    0.26



    Restructuring costs and certain other items (d)





    (28,881)





    -





    28,881





    1.4 %





    (651)





    28,230





    6,860





    21,370





    0.36



    Acquisition related costs (e)





    (13,298)





    -





    13,298





    0.6 %





    -





    13,298





    3,191





    10,107





    0.17



    Retention bonus obligation (f)





    (8,368)





    (2,790)





    11,158





    0.5 %





    -





    11,158





    2,678





    8,480





    0.14

    Adjusted Non-GAAP



    $

    505,110



    $

    127,769



    $

    627,200





    29.4 %



    $

    713



    $

    571,739



    $

    90,195



    $

    481,544



    $

    8.13





























































    ________________________________

    (a)

    Selling & administrative expenses include purchased intangibles amortization and litigation provisions and settlements.

    (b)

    The purchased intangibles amortization, a non-cash expense, was excluded to be consistent with how management evaluates the performance of its core business against historical operating results and the operating results of competitors over periods of time.

    (c)

    Litigation provisions and settlement gains were excluded as these items are isolated, unpredictable and not expected to recur regularly.

    (d)

    Restructuring costs and certain other items were excluded as the Company believes that the cost to consolidate operations, reduce overhead, and certain other income or expense items are not normal and do not represent future ongoing business expenses of a specific function or geographic location of the Company.

    (e)

    Acquisition related costs include all incremental expenses incurred, such as advisory, legal, accounting, tax, valuation, and other professional fees. The Company believes that these costs are not normal and do not represent future ongoing business expenses.

    (f)

    In connection with the Wyatt acquisition, the Company started to recognize a two-year retention bonus obligation that is contingent upon the employee's providing future service and continued employment with Waters. The Company believes that these costs are not normal and do not represent future ongoing business expenses.

     

    Waters Corporation and Subsidiaries

    Preliminary Condensed Unclassified Consolidated Balance Sheets

    (In thousands and unaudited)



























































    September 28, 2024



    December 31, 2023

















    Cash, cash equivalents and investments



    $                331,458



    $                395,974

    Accounts receivable







    669,534



    702,168

    Inventories







    518,994



    516,236

    Property, plant and equipment, net



    642,627



    639,073

    Intangible assets, net





    591,883



    629,187

    Goodwill









    1,306,593



    1,305,446

    Other assets







    450,531



    438,770

       Total assets







    $             4,511,620



    $             4,626,854

































    Notes payable and debt





    $             1,826,248



    $             2,355,513

    Other liabilities







    1,082,273



    1,121,000

       Total liabilities







    2,908,521



    3,476,513

















    Total stockholders' equity





    1,603,099



    1,150,341

       Total liabilities and stockholders' equity



    $             4,511,620



    $             4,626,854

     

    Waters Corporation and Subsidiaries

    Preliminary Condensed Consolidated Statements of Cash Flows

    Three and Nine Months Ended September 28, 2024 and September 30, 2023

    (In thousands and unaudited)

































    Three Months Ended





    Nine Months Ended









    September 28, 2024



    September 30, 2023





    September 28, 2024



    September 30, 2023

















    Cash flows from operating activities:



















    Net income

    $                     161,503



    $                   134,552





    $                   406,436



    $                   426,029



    Adjustments to reconcile net income to net























    cash provided by operating activities:





















    Stock-based compensation

    10,647



    8,490





    32,993



    32,224





    Depreciation and amortization

    47,507



    47,807





    143,250



    117,845





    Change in operating assets and liabilities and other, net

    (15,077)



    (33,031)





    (60,695)



    (203,411)







    Net cash provided by operating activities

    204,580



    157,818





    521,984



    372,687

























    Cash flows from investing activities:



















    Additions to property, plant, equipment























    and software capitalization

    (25,618)



    (38,047)





    (90,377)



    (119,044)



    Business acquisitions, net of cash acquired

    -



    -





    -



    (1,285,907)



    (Investments in) proceeds from unaffiliated companies

    (425)



    651





    (1,489)



    651



    Net change in investments

    (8)



    (5)





    (44)



    (21)







    Net cash used in investing activities

    (26,051)



    (37,401)





    (91,910)



    (1,404,321)

























    Cash flows from financing activities:



















    Net change in debt

    (180,000)



    (125,181)





    (530,000)



    929,601



    Proceeds from stock plans

    3,237



    9,464





    25,073



    18,092



    Purchases of treasury shares

    (141)



    (692)





    (13,475)



    (70,433)



    Other cash flow from financing activities, net

    20



    2,884





    15,305



    8,178







    Net cash used in financing activities

    (176,884)



    (113,525)





    (503,097)



    885,438

























    Effect of exchange rate changes on cash and cash equivalents

    2,442



    (171)





    8,461



    2,081







    Increase (decrease) in cash and cash equivalents

    4,087



    6,721





    (64,562)



    (144,115)

























    Cash and cash equivalents at beginning of period

    326,427



    329,693





    395,076



    480,529







    Cash and cash equivalents at end of period

    $                     330,514



    $                   336,414





    $                   330,514



    $                   336,414

































































































    Reconciliation of GAAP Cash Flows from Operating Activities to Free Cash Flow (a)









































































    Net cash provided by operating activities - GAAP

    $                     204,580



    $                   157,818





    $                   521,984



    $                   372,687



























    Adjustments:





















    Additions to property, plant, equipment























    and software capitalization

    (25,618)



    (38,047)





    (90,377)



    (119,044)





    Tax reform payments

    -



    -





    95,645



    72,101





    Litigation settlements (received) paid, net

    -



    (375)





    9,250



    (1,125)





    Major facility renovations

    -



    3,291





    -



    12,151





    Payment of acquired Wyatt liabilities (b)

    -



    -





    -



    25,617





    Payment of Wyatt retention bonus obligation (c)

    -



    -





    19,770



    -

    Free Cash Flow - Adjusted Non-GAAP

    $                     178,962



    $                   122,687





    $                   556,272



    $                   362,387

























    (a)

    The Company defines free cash flow as net cash flow from operations accounted for under GAAP less capital expenditures and software capitalizations plus or minus any unusual and non recurring items. Free cash flow is not a GAAP measurement and may not be comparable to free cash flow reported by other companies.

























    (b)

    In connection with the Wyatt acquisition, the Company assumed certain obligations of Wyatt and paid those obligations immediately upon closing the transaction. The Company believes that the assumed obligations do not represent future ongoing business expenses.

























    (c)

    During the nine months ended September 28, 2024, the Company made its first retention payment under the Wyatt retention bonus program. The Company believes that these payments are not normal and do not represent future ongoing business expenses.

     

    Waters Corporation and Subsidiaries

    Reconciliation of Projected GAAP to Adjusted Non-GAAP Financial Outlook















































    Twelve Months Ended



    Three Months Ended







    December 31, 2024



    December 31, 2024









    Range







    Range



    Projected Sales



































    Organic constant currency sales growth rate (a)

    (0.9 %)

    -

    (0.3 %)



    5.0 %

    -

    7.0 %

    Impact of:



















    Currency translation

    (1.2 %)

    -

    (1.2 %)



    (1.7 %)

    -

    (1.7 %)



    Acquisitions

    1.3 %

    -

    1.3 %



    ‒

    -

    ‒

    Sales growth rate as reported

    (0.8 %)

    -

    (0.2 %)



    3.3 %

    -

    5.3 %

















































    Range







    Range



    Projected Earnings Per Diluted Share



































    GAAP earnings per diluted share

    $    10.55

    -

    $    10.75



    $      3.72

    -

    $      3.92

    Adjustments:



















    Purchased intangibles amortization 

    $      0.60

    -

    $      0.60



    $      0.15

    -

    $      0.15



    Litigation settlement

    $      0.15

    -

    $      0.15



    $            -

    -

    $            -



    Restructuring costs and certain other items 

    $      0.14

    -

    $      0.14



    $            -

    -

    $            -



    Retention bonus obligation

    $      0.23

    -

    $      0.23



    $      0.03

    -

    $      0.03

    Adjusted non-GAAP earnings per diluted share

    $    11.67

    -

    $    11.87



    $      3.90

    -

    $      4.10





















    (a) Organic constant currency growth rates are a non-GAAP financial measure that measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period and excluding the impact of acquisitions made within twelve months of the acquisition close date. These amounts are estimated at the current foreign currency exchange rates and based on the forecasted geographical sales in local currency, as well as an assessment of market conditions as of today, and may differ significantly from actual results.





















    These forward-looking adjustment estimates do not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance.

     

    Contact:    Caspar Tudor, Head of Investor Relations – (508) 482-2429

    Cision View original content:https://www.prnewswire.com/news-releases/waters-corporation-nyse-wat-reports-third-quarter-2024-financial-results-302293299.html

    SOURCE Waters Corporation

    Get the next $WAT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WAT

    DatePrice TargetRatingAnalyst
    3/31/2025$460.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/26/2025$396.00 → $407.00Neutral → Outperform
    Robert W. Baird
    2/13/2025$450.00Sector Perform → Sector Outperform
    Scotiabank
    2/10/2025$360.00 → $415.00Underweight → Equal Weight
    Barclays
    1/10/2025$430.00Mkt Perform → Outperform
    Bernstein
    12/23/2024Sector Perform
    Scotiabank
    10/8/2024$355.00 → $415.00Hold → Buy
    Jefferies
    8/28/2024$380.00Overweight
    Wells Fargo
    More analyst ratings

    $WAT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Waters Corporation to Present at the Jefferies Global Healthcare Conference

      MILFORD, Mass., May 16, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4th, 2025, at 8:45AM Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will be available for 90 days. About Waters Corporation Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences f

      5/16/25 11:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Integrates Multi-Angle Light Scattering Detectors with Empower Software for Improved Biologics Quality Control and Simplified Regulatory Compliance

      News Summary  Saves up to six months on compliant software validation in biopharmaceutical quality control.1Reduces analysis time for biotherapeutic peptides and proteins by 20%.2Enhances quality control by providing absolute molecular weight of biologics and avoiding common errors encountered with other techniques.3MILFORD, Mass., May 6, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that its Empower™ Software now supports biologics data acquisition and quality control (QC) analysis from Multi-Angle Light Scattering (MALS) and differential Refractive Index (RI) instruments in its Wyatt Technology™ Portfolio. This integration expands the scope of critical quality attribut

      5/6/25 6:15:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Corporation (NYSE: WAT) Reports First Quarter 2025 Financial Results

      Highlights Strong start to the year as first quarter 2025 sales of $662 million landed at the high-end of guidance range; grew 4% as reported and 7% in constant currencyResults led by instrument growth of 11% in constant currency, driven by strong momentum in Pharma and Industrial end marketsEarnings landed at the high-end of guidance range with GAAP EPS of $2.03 and non-GAAP EPS of $2.25Raising full-year constant currency sales growth guidance to +5.0% to +7.0%, given first quarter strengthRaising full-year non-GAAP EPS guidance to the range of $12.75 to $13.05, net of tariff impact, operational actions, and improvement in FXFirst Quarter 2025 MILFORD, Mass., May 6, 2025 /PRNewswire/ -- Wat

      5/6/25 6:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP & Chief Financial Officer Chaubal Amol covered exercise/tax liability with 239 shares, decreasing direct ownership by 4% to 5,224 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      5/14/25 5:22:52 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SVP TA Instruments Division Bennett Jianqing covered exercise/tax liability with 303 shares, decreasing direct ownership by 6% to 4,916 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      4/8/25 5:43:17 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Jiang Wei was granted 53 shares, increasing direct ownership by 2% to 2,410 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      4/2/25 5:12:56 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Waters Corporation

      SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

      11/12/24 11:54:03 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Waters Corporation (Amendment)

      SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

      2/14/24 9:37:22 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Waters Corporation (Amendment)

      SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

      2/13/24 5:17:31 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Fearon Richard H bought $332,900 worth of shares (1,000 units at $332.90), increasing direct ownership by 153% to 1,653 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      5/29/24 11:23:35 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    SEC Filings

    See more
    • SEC Form 10-Q filed by Waters Corporation

      10-Q - WATERS CORP /DE/ (0001000697) (Filer)

      5/6/25 7:00:36 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Corporation filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - WATERS CORP /DE/ (0001000697) (Filer)

      5/6/25 6:05:51 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEFA14A filed by Waters Corporation

      DEFA14A - WATERS CORP /DE/ (0001000697) (Filer)

      4/9/25 4:16:58 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Waters upgraded by KeyBanc Capital Markets with a new price target

      KeyBanc Capital Markets upgraded Waters from Sector Weight to Overweight and set a new price target of $460.00

      3/31/25 7:57:55 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded Waters from Neutral to Outperform and set a new price target of $407.00 from $396.00 previously

      3/26/25 7:47:54 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters upgraded by Scotiabank with a new price target

      Scotiabank upgraded Waters from Sector Perform to Sector Outperform and set a new price target of $450.00

      2/13/25 8:14:37 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Financials

    Live finance-specific insights

    See more
    • Waters Corporation (NYSE: WAT) Reports First Quarter 2025 Financial Results

      Highlights Strong start to the year as first quarter 2025 sales of $662 million landed at the high-end of guidance range; grew 4% as reported and 7% in constant currencyResults led by instrument growth of 11% in constant currency, driven by strong momentum in Pharma and Industrial end marketsEarnings landed at the high-end of guidance range with GAAP EPS of $2.03 and non-GAAP EPS of $2.25Raising full-year constant currency sales growth guidance to +5.0% to +7.0%, given first quarter strengthRaising full-year non-GAAP EPS guidance to the range of $12.75 to $13.05, net of tariff impact, operational actions, and improvement in FXFirst Quarter 2025 MILFORD, Mass., May 6, 2025 /PRNewswire/ -- Wat

      5/6/25 6:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • Waters Corporation Schedules First Quarter 2025 Earnings Conference Call

      MILFORD, Mass., April 8, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q1 2025 financial results conference call on Tuesday, May 6th, 2025 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least June 3rd, 2025, at midnight Eastern Time. About Waters Corporation  Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food

      4/8/25 4:30:00 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Leadership Updates

    Live Leadership Updates

    See more
    • Waters Corporation Appoints Heather Knight to Board of Directors

      MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for

      8/14/24 4:15:00 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Corporation Appoints Richard Fearon to Board of Directors

      Waters™ Corporation (NYSE:WAT) today announced the appointment of Richard Fearon to its Board of Directors, effective March 27, 2023. Mr. Fearon is the former Vice Chairman and Chief Financial and Planning Officer of Eaton Corporation, a multinational power management company. "Rick's expertise is at the intersection of financial excellence, strategic development and transformation, which are the key pillars of Waters' growth plan. We are confident that Rick's unique skillset will complement our Board well and we look forward to benefiting from his insights as we continue to drive value for shareholders," said Dr. Flemming Ornskov, Chairman of the Board. Dr. Udit Batra, CEO and President,

      3/28/23 8:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Corporation Appoints Dan Brennan and Mark Vergnano to Board of Directors

      Waters Corporation (NYSE:WAT) today announced the appointment of Dan Brennan and Mark Vergnano, to its Board of Directors, effective November 23, 2022. Mr. Brennan currently serves as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation, a global medical device company, and Mr. Vergnano is the former Chairman, President and Chief Executive Officer of The Chemours Company, a chemistry company. "Dan and Mark are outstanding leaders whose decades of experience in the medical device and chemistry industries will add tremendous value as Waters continues to execute its exciting growth strategy," said Dr. Flemming Ornskov, Chairman of the Board. "These appointment

      11/23/22 8:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials